Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.68 |
| ▸ | RECQL | P46063 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | TEK | Q02763 | 1/20 | 0.68 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | RARB | P10826 | 1/20 | 0.58 |
| ▸ | RARG | P13631 | 1/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbenicillin Phenyl SCHEMBL150616 | 1.00 | KDM4E (0.68) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL10734854 | 1.00 | KDM4E (0.68) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL11310099 | 1.00 | KDM4E (0.68) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL586468 | 0.99 | KDM4E (0.67) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL11308037 | 0.99 | KDM4E (0.67) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL11475569 | 0.99 | KDM4E (0.67) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL11310839 | 0.94 | LMNA (0.64) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL11310852 | 0.94 | LMNA (0.64) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL192220 | 0.92 | LMNA (0.79) | KDM4ERECQLTDP1KMT2APOLB | |
| Carbenicillin Phenyl SCHEMBL11308035 | 0.92 | LMNA (0.79) | KDM4ERECQLTDP1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| US-20230149514-A1 | CROSSLINKED PARTICLES, COMPOSITION COMPRISING THE CROSSLINKED PARTICLES, METHOD FOR THE MANUFACTURE THEREOF, AND METHOD OF TREATING AN INFECTION | UNIVERSITY OF MASSACHUSETTS | 2023-05-18 | — | — | US | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-11110209-B2 | Intraluminal therapy system for gastrointestinal infections | MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL (TW) | 2021-09-07 | — | — | US | claimed |
| US-20200246573-A1 | NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS | STREETERVILLE CAPITAL, LLC | 2020-08-06 | — | — | US | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | claimed |
| US-20180221542-A1 | INTRALUMINAL THERAPY SYSTEM FOR GASTROINTESTINAL INFECTIONS | MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL (TW) | 2018-08-09 | — | — | US | claimed |
| EP-0083977-A1 | 6-Alpha-hydroxymethylpenicillanic acid sulfone as a beta-lactamase inhibitor | PFIZER INC. (US) | 1983-07-20 | — | — | EP | claimed |
| US-4381307-A | Soft tertiary amine esters of bio-affecting carboxylic acids | MERCK & CO., INC. (US) | 1983-04-26 | — | — | US | claimed |
| US-4376767-A | ANTIBIOTICS AND PHARMACEUTICALS | MERCK & CO., INC. (US) | 1983-03-15 | — | — | US | claimed |
| EP-0008917-B1 | PENAM-3-CARBOXYLIC ACID 1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | PFIZER INC. (US) | 1982-11-24 | — | — | EP | claimed |
| EP-0055870-A1 | Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-07-14 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| EP-0050965-A1 | Beta-lactamase inhibitory composition | Takeda Chemical Industries, Ltd. (JP) | 1982-05-05 | — | — | EP | claimed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | claimed |
| US-4256733-A | Acetoxymethyl penam compounds as β-lactamase inhibitors | PFIZER INC. (US) | 1981-03-17 | — | — | US | claimed |
| EP-0008917-A1 | Penam-3-carboxylic acid 1,1-dioxides, process for their preparation and pharmaceutical compositions | PFIZER INC. (US) | 1980-03-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | KDM4E 1604/4885RECQL 4094/4885TDP1 1655/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | KDM4E 1604/4885RECQL 4094/4885TDP1 1655/4885 |
| US-20230149514-A1 | CROSSLINKED PARTICLES, COMPOSITION COMPRISING THE CROSSLINKED PARTICLES, METHOD FOR THE MANUFACTURE THEREOF, AND METHOD OF TREATING AN INFECTION | COL1A1, COL14A1, COL2A1 | KDM4E 4010/4885RECQL 1320/4885TDP1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.